Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis

Warisara Siricharoonwong* and Rattana Boonsirichan

*Division of Gastroenterology, Department of Internal Medicines, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand*

*Corresponding Author: Warisara Siricharoonwong, Division of Gastroenterology, Department of Internal Medicines, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.*

**Received:** December 09, 2019; **Published:** February 06, 2020

**Abstract**

**Background:** Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of cirrhosis worldwide. A considerable amount of patients without DM still has NASH and advanced fibrosis. *Helicobacter pylori* (*H. pylori*) infection contribute to the increase in levels of pro-inflammatory cytokines which have different metabolic effects and associated with insulin resistance (IR). Therefore, *H. pylori* may possibly have an effect on fibrosis progression in NAFLD in nondiabetic patients.

**Objectives:** Our study aims to investigate the prevalence of *H. pylori* infection in non-diabetic NAFLD patient and its association in advance fibrosis.

**Method:** Nondiabetic patients who were diagnosed NAFLD by abdominal ultrasonography and/or controlled attenuation parameter (CAP) from FibroScan® were recruited for *H. pylori* infection testing by a 14C-urea breath test. All participants were evaluated liver fibrosis with transient elastography. They were collected standard biochemical test (e.g. FPG, LDL, liver function test) and interleukin-6 to evaluate the inflammatory response. To minimized the confounding effect, we excluded patients who had BMI > 28 kg/m² or received steatogenic drugs. The outcome was the prevalence of *H. pylori* infection in NAFLD patients. We also investigated factors which independently associated with advanced fibrosis.

**Result:** A total of 117 NAFLD patients were enrolled. We found overall *H. pylori* infection in 54 patients (46%). In patients with advanced fibrosis (defined as fibrosis stage ≥ 3 from transient elastography), the prevalence of advanced hepatic fibrosis in NAFLD patients with *H. pylori* infection is higher (22/54, 40.7%) than in non-infected group (18/63, 28.6%). Obesity was the variable most associated with advanced fibrosis (OR 3.18 [1.25 - 8.09], p-value 0.02) in univariate analysis. *H. pylori* infection had a marginal effect to advanced fibrosis (OR 1.72 [0.8 - 3.71], p-value 0.17) but no statistically significant in multivariate analysis. Other metabolic variables and interleukin-6 were not significantly associated with advanced fibrosis.

**Conclusion:** Prevalence of *H. pylori* infection in nondiabetic NAFLD patient similar to the general Thai population. Our results could not demonstrate the risk of *H. pylori* infection to advanced fibrosis. However, NAFLD patients with *H. pylori* infection tend to have a higher prevalence of advance hepatic fibrosis.

**Keywords:** Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Fatty Liver (NAFL); Nonalcoholic Steatohepatitis (NASH); Liver Cirrhosis (LC); *Helicobacter pylori* (*H. pylori*)

**Citation:** Warisara Siricharoonwong and Rattana Boonsirichan. “Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis”. *EC Gastroenterology and Digestive System* 7.3 (2020): 01-09.
Background

Nonalcoholic fatty liver disease is one of the most common causes of cirrhosis worldwide. The significance of NAFLD is currently considered to be the most common liver disorder in western countries, affecting up to 25%-30% of individuals among the general population and almost 70% among obese subjects [1,2]. NAFLD has a board spectrum range from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), which may progress to liver cirrhosis (LC).

NAFLD is now regarded as the liver manifestation of the metabolic syndrome. It is strongly associated with obesity, diabetes, cardiovascular disease (CVD), dyslipidemia and insulin resistance (IR) [1]. A considerable amount of patients without DM still had NASH (64%) and advanced fibrosis (17%) [3].

Approximately one-third of NAFLD patients progress in the fibrosis stage during average 4 to 5 year of follow-up, some of whom have a more rapid course. Advanced fibrosis (stage 3 - 4) was an independent predictor of overall and disease-specific mortality of NAFLD [4]. In previous analysis showed old aged and inflammation from liver biopsy is an independent factor associated with progression to liver fibrosis [4].

Helicobacter pylori (H. pylori) infection is one of the most common gastrointestinal infections in humans. The chronic, low-grade inflammation (CLGI) of H. pylori contributes to the increase in levels of pro-inflammatory cytokines secreted into circulation which has different metabolic effects [5]. In view of this effect on metabolic variables, H. pylori is associated with insulin resistance (IR). Therefore, H. pylori could predispose patients to NAFLD because of chronic inflammatory state and associated metabolic derangement [1].

The association between H. pylori infection and NAFLD has been demonstrated in several clinical trials. In previous several studies, the prevalence of NAFLD was significantly higher in the patients with H. pylori infected than in those without [6-8]. There are also some studies demonstrating a higher prevalence of H. pylori infection in cirrhotic patients with chronic hepatitis C [9]. H. pylori may influence the fibrosis progression in chronic hepatitis C [10]. Extrapolation from this study, we hypothesize H. pylori possibly have an effect on fibrosis progression in NAFLD. Despite, there have been few reports considering the potential effect between H. pylori infection and the clinical of NAFLD but the majority of the patient group was diabetes which may be a confounding factor of disease severity. Interestingly, NAFLD patients without DM may have another hit to develop insulin resistance and also fibrosis progression other than diabetes. Therefore, we investigated the H. pylori status in nondiabetic NAFLD with significant liver fibrosis and evaluate the variables predicting in significant fibrosis in nondiabetic NAFLD.

Material and Methods

Patients

Non-diabetes patients with NAFLD were enrolled to our study. The diagnosis of NAFLD was based on the following criteria: [1] evidence of fatty liver from abdominal ultrasonography and/or transient elastography show controlled attenuation parameter (CAP) more than 5% steatosis [11]; Stage 0 < 5% steatosis, Stage 1≥ S1: 5 - 33% steatosis, stage 2 (≥ S2: 34% - 66% steatosis) and stage 3 (≥S3: > 66% steatosis) [2] exclusion of liver diseases of other etiology.

All of the patients have no history of consuming more than 10 g of alcohol in female and 20 g in male per day. Informed consent will be obtained from all patients. The exclusion criteria are [1] alcohol consumption excess the limit of NAFLD diagnosis. [2] pregnancy [3] the evidence of decompensated cirrhosis or HCC [4] patients who received steatogenic drugs; corticosteroids, methotrexate, amiodarone [5] patients who had BMI > 28 kg/m².

Laboratory parameters

Baseline demographic features will be measured in body weight (kg) and height (m). BMI will be calculated by using the following formula: weight in kg/ (height in m²). Obesity defines as BMI over than 24.9 according to WHO classification of obesity in Asia.

Citation: Warisara Siricharoonwong and Rattana Boonsirichan. "Prevalence of Helicobacter pylori Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis". EC Gastroenterology and Digestive System 7.3 (2020): 01-09.
Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis

Venous blood will be drawn from every patient. The laboratory evaluation measures of the following levels:

- Liver function test: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, albumin, bilirubin.
- Complete blood count (CBC), platelets count.
- Lipid profile: total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C).
- Fasting plasma glucose.
- Insulin level.
- Pro-inflammatory cytokines: Interleukin-6 (IL-6).

The HOMA-IR will be calculated on the basis of the fasting values of plasma glucose and insulin according to the HOMA model formula: HOMA-IR = fasting insulin level (mU/L) x Fasting plasma glucose (mg/dL)/405.

A high HOMA-IR score denotes low insulin sensitivity and insulin resistance.

NAFLD fibrosis score (NFS) will be use to predict disease severity.

Non-invasive fibrosis score; NAFLD fibrosis score will be calculated to evaluate the severity according to the following formula:

\[
\text{NAFLD Score} = -1.675 + (0.037 \times \text{age [years]}) + (0.094 \times \text{BMI [kg/m}^2\text{]}) + (1.13 \times \text{IFG/diabetes [yes = 1, no = 0]}) + (0.99 \times \text{AST/ALT ratio}) - (0.013 \times \text{platelet count [×10}^9\text{/L]}) - (0.66 \times \text{albumin [g/dl]})
\]

The AST-to-Platelet Ratio Index (APRI) was a good predictor for advanced fibrosis in NAFLD patients area under the ROC curve 0.8307 [13].

\[
\text{APRI index} = \left\{ \left( \frac{\text{AST level/AST upper normal limit}}{\text{platelet count} \times 10^9} \right) \right\} \times 100
\]

All of the participants was evaluated the degree of liver steatosis and fibrosis by FibroScan® which represented in controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). The standard M probe will be used in the patient with BMI < 28 kg/m². The advanced fibrosis is considered at ≥ F 3 stage.

A complete 13C-Urease breath test was used for the diagnosis of active *H. pylori* infection status.

We investigated the prevalence of *H. pylori* in NAFLD. Laboratory parameters and clinical data were investigated which independently associated with advanced fibrosis of the liver.

**Statistical analysis**

The results were presented as medians and interquartile ranges for quantitative data or as numbers with percentages for qualitative data. Significant differences in categorical data will be determined by using the Chi-square test or Fisher’s exact test. The Mann-Whitney U test was used for comparison of continuous data. A multivariate analysis will be performed by logistic regression analysis to identify which variables associated with advanced fibrosis in nondiabetic NAFLD. Differences consider statistically significant at all p-values less than 0.05. Statistical analyses were performed using Stata/SE 14.0 for windows, 2015.

**Results**

A total of 117 participants was included in this study. Demographic and summaries of the clinical and laboratory data of the population were presented in table 1. There were no significant differences in age, gender distribution, body mass index between *H. pylori* infected

---

**Citation:** Warisara Siricharoonwong and Rattana Boonsirichan. “Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis”. *EC Gastroenterology and Digestive System* 7.3 (2020): 01-09.
and non-infected group. The 70% of participants were obese (BMI over than 24.9), had insulin resistance and impaired fasting glucose. According to the controlled attenuation parameter (CAP) from FibroScan®, level of liver steatosis in *H. pylori* infected group was lower than another (Figure 2). Other clinical parameters were similar between the two groups (Table 1). Interleukin-6, pro-inflammatory cytokines also was not different in both *H. pylori* infected or non-infected group (Figure 3). Prevalence of overall *H. pylori* infection is 46%. But in patients with advanced fibrosis (defined as fibrosis stage ≥ 3 from transient elastography). The prevalence of advanced hepatic fibrosis in NAFLD patients with *H. pylori* infection is higher (22/54, 40.7%) than in non-infected group (18/63, 28.6%) (Figure 4). The non-invasive scoring system, NAFLD fibrosis score and APRI score was no difference between two group (p = 0.46).

The association of *H. pylori* and advanced fibrosis in NAFLD was examined (Table 2). Univariate analysis revealed that obesity (BMI > 25 kg/m²) was only an independent variable associated with advanced fibrosis in NAFLD (OR 3.18 [1.25 - 8.09], p-value 0.02). *H. pylori* infection tend to affect severity of fibrosis in NAFLD (OR 1.72 [0.8 - 3.71], p-value 0.17). However, multivariate analysis revealed no independent variable associated with fibrosis.

**Citation:** Warisara Siricharoonwong and Rattana Boonsirichan. “Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis”. *EC Gastroenterology and Digestive System* 7.3 (2020): 01-09.
### Variables of study participants at baseline.

<table>
<thead>
<tr>
<th>Variables</th>
<th>H. pylori Negative (n = 63)</th>
<th>H. pylori Positive (n = 54)</th>
<th>All (n = 117)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57.86 (±11.5)</td>
<td>56.44 (±11.2)</td>
<td>57.20 (±11.3)</td>
<td>0.50</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>23 (36.5%)</td>
<td>24 (44.4%)</td>
<td>47 (40.2%)</td>
<td>0.76</td>
</tr>
<tr>
<td>Female</td>
<td>40 (63.5%)</td>
<td>30 (55.6%)</td>
<td>70 (59.8%)</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.12 (±3.0)</td>
<td>26.97 (±3.2)</td>
<td>26.51 (±3.1)</td>
<td>0.14</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>19 (30.2%)</td>
<td>14 (25.9%)</td>
<td>33 (28.2%)</td>
<td>0.25</td>
</tr>
<tr>
<td>No</td>
<td>44 (69.8%)</td>
<td>40 (74.1%)</td>
<td>84 (71.8%)</td>
<td></td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>109 (±14.1)</td>
<td>104 (±11.9)</td>
<td>107 (±13.3)</td>
<td>0.04</td>
</tr>
<tr>
<td>HBA1C</td>
<td>5.96 (±0.56)</td>
<td>5.8 (±0.49)</td>
<td>5.93 (±0.53)</td>
<td>0.45</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>129.25 (±39.8)</td>
<td>123.46 (±35.5)</td>
<td>126.58 (±37.6)</td>
<td>0.41</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>132.34 (±61.1)</td>
<td>114 (±48.4)</td>
<td>124 (±56.1)</td>
<td>0.07</td>
</tr>
<tr>
<td>AST (U/l)</td>
<td>35.25 (±15.5)</td>
<td>33.20 (±19.5)</td>
<td>34.30 (±17.4)</td>
<td>0.53</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>52.04 (±24)</td>
<td>55.20 (±71)</td>
<td>53.50 (±36.6)</td>
<td>0.64</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>5.23 (0.82-32.1)</td>
<td>4.88 (0.75-23.3)</td>
<td>5.07 (0.75-32.1)</td>
<td>0.70</td>
</tr>
<tr>
<td>IL-6</td>
<td>3.48 (±2.9)</td>
<td>3.39 (±2.65)</td>
<td>3.45 (±2.78)</td>
<td>0.86</td>
</tr>
<tr>
<td>NAFLD fibrosis score</td>
<td>-1.30 (±1.40)</td>
<td>-1.55 (±1.33)</td>
<td>-1.41 (±1.37)</td>
<td>0.74</td>
</tr>
<tr>
<td>APRI score</td>
<td>0.44 (±0.27)</td>
<td>0.39 (±0.31)</td>
<td>0.42 (±0.291)</td>
<td>0.46</td>
</tr>
</tbody>
</table>

**Table 1:** Characteristics of study participants at baseline.

**Figure 2:** CAP in patients with and without H. pylori.

---

**Citation:** Warisara Siricharoonwong and Rattana Boonsirichan. "Prevalence of Helicobacter pylori Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis". *EC Gastroenterology and Digestive System* 7.3 (2020): 01-09.
Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis

**Figure 3:** Interleukin-6 in patients with and without *H. pylori*.

**Figure 4:** Fibrosis stage in patients with and without *H. pylori*.

Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis

<table>
<thead>
<tr>
<th>Variables</th>
<th>Univariate</th>
<th></th>
<th></th>
<th>Multivariate</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95%LCI</td>
<td>95%UCI</td>
<td>p-value</td>
<td>OR</td>
<td>95%LCI</td>
</tr>
<tr>
<td><em>H. pylori</em> infection</td>
<td>1.72</td>
<td>0.80</td>
<td>3.71</td>
<td>0.17</td>
<td>1.30</td>
<td>0.62</td>
</tr>
<tr>
<td>Obesity (BMI&gt;25)</td>
<td>3.18</td>
<td>1.25</td>
<td>8.09</td>
<td>0.02</td>
<td>1.57</td>
<td>0.67</td>
</tr>
<tr>
<td>IFG</td>
<td>1.25</td>
<td>0.57</td>
<td>2.77</td>
<td>0.58</td>
<td>1.54</td>
<td>0.69</td>
</tr>
<tr>
<td>DLP</td>
<td>0.68</td>
<td>0.30</td>
<td>1.51</td>
<td>0.34</td>
<td>0.74</td>
<td>0.33</td>
</tr>
<tr>
<td>HOMA-IR &gt; 2.5</td>
<td>1.50</td>
<td>0.60</td>
<td>3.77</td>
<td>0.39</td>
<td>1.22</td>
<td>0.49</td>
</tr>
</tbody>
</table>

*Table 2: Univariate and multivariate analyses to identify independent variables associated with advance fibrosis.*

**Discussion**

In the previous study in Japan, the *H. pylori* status in NAFLD was 40% [8]. But almost of subjects in the study had diabetes and they evaluated *H. pylori* status by anti-*H. pylori* IgG level which had low accuracy due to the inability to differentiate between current and past infection [15]. This study is the first to show the prevalence of *H. pylori* in NAFLD who had no diabetes mellitus and we tested *H. pylori* status by urea breath tests which had high diagnostic accuracy. We found that the prevalence of *H. pylori* in non-diabetic NAFLD in our study (46%) was not different compared with the overall prevalence in Thailand nationwide (45.9%) [16]. From global prevalence, Asia was a moderate rate of infection area [17]. Some studies from highly endemic areas of *H. pylori* found no association between positive *H. pylori* serology and NAFLD [18,19].

DM and obesity are the factors contributing to more severe NAFLD and accelerates the progression of hepatic fibrosis. Therefore, we excluded these specific groups to avoid the confounding effect. In advanced fibrosis NAFLD patients, the prevalence of *H. pylori* infection was higher than the non-infected group. This data may indicate an influence of *H. pylori* to hepatic fibrosis in NAFLD. Evidence of chronic *H. pylori* infection promoted hepatic fibrosis was shown in one animal model study [20]. Chronic infection stimulated profibrogenic cytokine (TGF-β) contributing to the production of extracellular matrix by activation of hepatic stellate cells (HSCs). However, univariate and multivariate analysis showed no association of *H. pylori* and the severity of fibrosis. The result may be due to the small sample subjects.

Our results in the grading of liver steatosis represented by controlled attenuation parameter (CAP) show an average of CAP value in *H. pylori* infected group was significantly lower than the non-infected group. On the other hand, we found advance fibrosis participants who had *H. pylori* infected more than the non-infected group. This finding may because of CAP was inversely correlated with the grading of fibrosis. High CAP value imply a lower risk of fibrosis/cirrhosis [21]. In consistent with lipid profile, triglyceride and LDL in *H. pylori* non-infected group was higher than infected group. But this might because the participants in *H. pylori* took lipid lowering drugs more than non-infected group.

The non-invasive scoring system such as NAFLD fibrosis score and APRI index has high accuracy for advanced fibrosis exclusion in low cut off. Both of scoring system, we found no difference between NAFLD with and without *H. pylori* infection. Most of participants were classified into an intermediate group which needed other modality testings to define the advance fibrosis. FibroScan®, the other test to evaluate liver fibrosis, transient elastography with controlled attenuation parameter (CAP) has demonstrated a good accuracy in quantifying the levels of liver steatosis and fibrosis in patients with NAFLD [11,14]. Although only these scoring systems were not a sufficient tool to predict the advanced fibrosis, NFS found to have an acceptable sensitivity, specificity to predict advanced liver fibrosis [12]. Utility of non-invasive score can avoiding up to 75% of liver biopsies.

The variety of inflammatory cytokines involved in *H. pylori* infection. Increase in IL-6 in the serum and tissue level reflected low-grade chronic inflammation in human. Some study showed an association between serum anti-*H. pylori* IgG levels and serum IL-6 levels in *H. pylori*

**Citation:** Warisara Siricharoonwong and Rattana Boonsirichan. “Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis”. *EC Gastroenterology and Digestive System* 7.3 (2020): 01-09.
Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis

*pylori*-infected adults [22]. NAFLD also had an increase of pro-inflammatory cytokines by itself [23]. However, in our study IL-6 level showed no difference between *H. pylori* infected and non-infected group. Moreover, much of Interleukin studies have been performed *in vitro*, so that their *in vivo* importance is less clear [5].

A strength of our study, we tested *H. pylori* infection by urea breath tests which reflected current infective status. It differed from the previous study that mostly used anti-*H. pylori* IgG level. Our study has some limitations. First, this is a cross-sectional, preliminary in an only single center in Bangkok area. Second, our sample size was small number. At last, we were limited the standard of evaluation the degree of fibrosis by liver biopsy. Nowadays, a non-invasive method for diagnosis of NAFLD such as FibroScan® is widely used instead of liver biopsy. Because it provides a high rate of accuracy and has less complication. Further large case-control studies are needed to identify the association between *H. pylori* infection and fibrosis in NAFLD. A randomized controlled trials are also needed to determine whether *H. pylori* eradication therapy can improve NAFLD with advanced fibrosis.

**Conclusion**

The prevalence of *H. pylori* in NAFLD patients revealed no difference compared with the general population in Thailand. However, *H. pylori* infection may be another contributing factor in fibrosis progression in nondiabetics NAFLD patients.

**Acknowledgement**

We would like to thank the Faculty of Medicine Vajira Hospital, Navamindradhiraj University for the funding support.

**Bibliography**


**Citation:** Warisara Siricharoonwong and Rattana Boonsirichan. "Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis". *EC Gastroenterology and Digestive System* 7.3 (2020): 01-09.
Prevalence of *Helicobacter pylori* Infection in Nondiabetic NAFLD and its Association in the Severity of Fibrosis


